Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

KPRX Kiora Pharmaceuticals

Watchlist
7.820
+0.710+9.99%
Close 10/04 16:00 ET
8.110
+0.29+3.71%
Post Mkt Price 10/04 19:59 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
8.520
Open
7.510
Turnover
4.16M
Low
7.510
Pre Close
7.110
Volume
527.21K
Market Cap
8.44M
P/E(TTM)
Loss
52wk High
87.600
Shares
1.08M
P/E(Static)
Loss
52wk Low
4.860
Float Cap
5.30M
Bid/Ask %
9.09%
Historical High
21000.000
Shs Float
677.37K
Volume Ratio
0.42
Historical Low
4.840
Dividend TTM
--
Div Yield TTM
--
P/B
0.96
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
77.83%
Amplitude
14.21%
Avg Price
7.881
Lot Size
1
Float Cap
5.30M
Bid/Ask %
9.09%
Historical High
21000.000
Shs Float
677.37K
Volume Ratio
0.42
Historical Low
4.840
Dividend TTM
--
P/B
0.96
Dividend LFY
--
Turnover Ratio
77.83%
Amplitude
14.21%
Avg Price
7.881
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
CEO: Strem Ph.D., Brian M.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top